Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsSXTC +31.21%34 Earnings Yield (Joel Greenblatt) % is 24.15% as of Mar. 2026, which is 53% above its 10-year median of 15.76. GuruFocus rates SXTC with a GF Score™ of 34/100. The stock has 8 warning signs investors should review. Among 1,009 Drug Manufacturers companies, China SXT Pharmaceuticals ranks worse than 99107.93% on this metric.
China SXT Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $-25.44 Mil.
China SXT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.14 Mil. China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 24.15%.
The historical rank and industry rank for China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SXTC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70.36 Med: 15.76 Max: 24.88
Current: 24.81
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of China SXT Pharmaceuticals was 24.88%. The lowest was -70.36%. And the median was 15.76%.
SXTC's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.02
vs SXTC: 24.81
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. China SXT Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
China SXT Pharmaceuticals (NAS:SXTC) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
China SXT Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
China SXT Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
China SXT Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
China SXT Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 24.15% mean?
China SXT Pharmaceuticals (SXTC) has a Earnings Yield (Joel Greenblatt) % of 24.15% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China SXT Pharmaceuticals and its competitors. This is 53% above median its historical median of 15.76. According to the industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 1009 companies in the Drug Manufacturers industry.
Is China SXT Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
China SXT Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % of 24.15% is 53% above median its 10-year median of 15.76. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.02. China SXT Pharmaceuticals' value of 24.15% is 699.7% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #999999 out of 1009 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 1009 companies for Earnings Yield (Joel Greenblatt) %. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.02. China SXT Pharmaceuticals' value of 24.15% is 699.7% above this benchmark. While the company's 10-year median is 15.76 vs. the industry median of 3.02, China SXT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.02, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 24.15% is 699.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 24.15%, which is 53% above median its own 10-year median of 15.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (SXTC) has a current Earnings Yield (Joel Greenblatt) % of 24.15%. The current Earnings Yield (Joel Greenblatt) % is 24.15%, which is 53% above median its 10-year median of 15.76 and 699.7% above the Drug Manufacturers industry median of 3.02. China SXT Pharmaceuticals' overall GF Score™ is 34/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current Earnings Yield (Joel Greenblatt) % is 24.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
34GF Score
Get the complete analysis for SXTC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTC has been successfully added to your 
